Compare Moderna, Inc. (MRNA) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Moderna, Inc. trades at $63.87 (market cap $24.18B), while Consumer Discretionary Select Sector SPDR Fund trades at $118. Which is the better fit depends on your goals.
| MRNA | XLY | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | — |
52-Week High | $81.80 | $124.52 |
52-Week Low | $22.36 | $105.64 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
XLY trades at $118.93, down 0.62% today, with a bullish technical signal from moving averages and neutral oscillators. Analyst consensus is unanimously positive with a 100% buy rating. The ETF shows strong technical momentum, though RSI levels indicate potential overbought conditions near-term.
The outlook remains favorable given bullish analyst sentiment and technical trends, but risks include consumer spending sensitivity to inflation and concentrated holdings. Upside potential hinges on sustained discretionary spending, while economic slowdowns pose a threat to performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
